Company

NEX-I, Inc.

NEX-I develops immuno-cancer drugs aimed at improving responses to immunotherapy.

About

Founded in 2021 and based in Seoul, NEX-I researches immunotherapy for cancer patients who do not respond to existing treatments. In May 2026, it raised KRW 50 billion in pre-IPO funding from Korea Development Bank, DS Asset Management, and InterVest. Returning investors included DSC Investment, Atinum Investment, T.S. Investment, WONIK Investment Partners, Hana Ventures, K2 Investment Partners, KB Investment, AJU IB Investment, QUAD Investment Management, Company K Partners, and Korea Investment & Securities.

6Funding rounds

22Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in